Concord Biotech Ltd (CONCORDBIO)
₹1,245.60
Mkt cap
₹13,031 Cr
P/E ratio
43.80
P/B
6.26
Div yield
0.30%
ROE
12.60%
ROCE
17.40%
EPS (TTM)
₹28.44
Book value
₹199
52W range
987–1,615
Sector
Healthcare
Price history
Previous close
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. [1]
NSE CONCORDBIOBSE 543960
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−22.87% from high₹1,246
₹987+26.20% from low₹1,615
Current
₹1,245.60
Prev close
₹1,230.60
Day
+1.22%
Price performance
1D
+1.25%
1W
+1.36%
1M
−11.68%
3M
−6.32%
6M
+9.83%
1Y
−17.63%
YTD
−5.02%
Financials
Revenue, profit & margin
P/E ratio
43.8×
CONCORDBIO is 27% above the sector median of 34.4×
CONCORDBIO43.8×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 261 | 312 | |
| Expenses | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 | 204 | 173 | 202 | |
| Operating Profit | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 | 122 | 87 | 110 | |
| OPM % | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% | 38% | 33% | 35% | |
| Other Income | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 | 16 | 13 | 10 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 19 | 18 | 18 | |
| Profit before tax | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 | 118 | 82 | 102 | |
| Tax % | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | 26% | 26% | |
| Net Profit | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 | 90 | 61 | 76 | |
| EPS in Rs | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 | 6.48 | 8.60 | 5.85 | 7.24 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.67% · closed higher next day 5 of last 14
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Feb '24 | 24 May '24 | 9 Aug '24 | 12 Nov '24 | 14 Feb '25 | 29 May '25◦ | 8 Aug '25◦ | 13 Nov '25◦ | 11 Feb '26◦ | 29 May '26◦ | 31 Jul '26◦ | 27 Oct '26◦ |
| Earnings day | −1.23% | −0.52% | −2.01% | −1.10% | −19.86% | +4.90% | +0.38% | +2.77% | −1.28% | +0.96% | −0.44% | −7.77% |
| +1 day | −2.66% | −1.26% | −4.72% | −1.55% | −20.33% | +9.15% | +3.15% | +2.98% | −4.85% | +10.94% | −0.06% | −10.52% |
| +5 days | −0.77% | +0.29% | +3.57% | +5.75% | −21.85% | +15.58% | +3.05% | −2.13% | −10.24% | +13.84% | −0.13% | — |
| +15 days | +0.24% | +4.89% | +9.40% | +16.75% | −20.58% | +10.22% | +6.31% | −3.45% | −3.02% | +27.25% | +8.35% | — |
| +30 days | +1.49% | +15.76% | +50.26% | +14.99% | −19.66% | +8.18% | +1.98% | −8.40% | −18.19% | +26.29% | +3.67% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| bonus Bonus 1:1 | 1.00 | 4 Nov '26 | 4 Nov '26 |
| dividend Dividend - Rs 7.55 Per Share | 7.55 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Sep 202644.09%Promoter
Promoters44.09%0.01
FIIs7.28%0.25
DIIs10.95%1.58
Public37.68%1.36
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Concord Biotech | ₹1,245.60 | 43.85 | 13,031 | 0.30% | 76 | +20.37% | 312 | +26.41% | 17.43% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports3
Concall transcripts32
PPTOct 2026RECOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 28 Oct - Q2 and half-year FY27 earnings call recording hosted on company website.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Concord Biotech will attend a UBS non-deal roadshow in Singapore on 3-4 November 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Oct - Press release - For the Second quarter and half year ended on September 30, 2026Announcement under Regulation 30 (LODR)-Investor Presentation 27 Oct - Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026Intimation Of Record Date For Issuance Of Bonus Equity Shares - November 04, 2026 27 Oct